Revolution Medicines (RVMD)
NASDAQ:RVMD
Want to see RVMD full AI Analyst Report?
RVMD Stock Chart & Stats
$148.63
$0.52(1.17%)
At close: 4:00 PM EST
$148.63
$0.52(1.17%)
Day’s Range― - ―
52-Week Range$34.00 - $155.01
Previous CloseN/A
Volume180.68K
Average Volume (3M)2.74M
Market Cap
$30.23B
Enterprise Value$29.23B
Total Cash (Recent Filing)$2.03B
Total Debt (Recent Filing)$158.70M
Price to Earnings (P/E)―
Beta1.09
Next Earnings
May 11, 2026EPS Estimate
-1.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.86
Shares Outstanding198,173,400
10 Day Avg. Volume4,344,379
30 Day Avg. Volume2,740,432
Financial Highlights & Ratios
PEG Ratio-0.20
Price to Book (P/B)9.28
Price to Sales (P/S)0.00
P/FCF Ratio-16.57
Enterprise Value/Market Cap0.97
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.44K
Enterprise Value/Ebitda-25.74
Forecast
1Y Price Target
$158.82Price Target Upside6.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
EPS Forecast (FY)-7.76
Revenue Forecast (FY)$60.47M
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsPhase 3 RASolute-302 demonstrated a clear survival improvement for daraxonrasib versus chemotherapy, providing strong efficacy evidence that reduces clinical risk and supports regulatory filings.
Commercial OpportunityAnalyst expectations for a robust commercial launch and potential broad use in pancreatic cancer imply meaningful revenue upside and stronger investor conviction if uptake matches projections.
Regulatory PathwayPlanned New Drug Application submission supported by a Commissioner's Priority Voucher could enable an expedited regulatory review and accelerate time to market if approval is granted.
Bears Say
Competitive LandscapeA highly competitive field of RAS-targeting therapies with potentially better efficacy or safety may challenge market adoption and make enrollment for future trials more difficult.
Financial OutlookSignificantly higher operating expenses for clinical development, manufacturing, and commercial preparations could pressure earnings and valuation unless offset by additional financing or partnerships.
Safety And TolerabilityFrequent skin rashes, gastrointestinal side effects, and cases of severe tolerability that prevent treatment could limit patient access and reduce the drug's addressable market.
Revolution Medicines News
RVMD FAQ
What was Revolution Medicines’s price range in the past 12 months?
Revolution Medicines lowest stock price was $34.00 and its highest was $155.01 in the past 12 months.
What is Revolution Medicines’s market cap?
Revolution Medicines’s market cap is $30.23B.
When is Revolution Medicines’s upcoming earnings report date?
Revolution Medicines’s upcoming earnings report date is May 11, 2026 which is in 22 days.
How were Revolution Medicines’s earnings last quarter?
Revolution Medicines released its earnings results on Feb 25, 2026. The company reported -$1.86 earnings per share for the quarter, missing the consensus estimate of -$1.581 by -$0.279.
Is Revolution Medicines overvalued?
According to Wall Street analysts Revolution Medicines’s price is currently Undervalued.
Does Revolution Medicines pay dividends?
Revolution Medicines does not currently pay dividends.
What is Revolution Medicines’s EPS estimate?
Revolution Medicines’s EPS estimate is -1.83.
How many shares outstanding does Revolution Medicines have?
Revolution Medicines has 198,173,400 shares outstanding.
What happened to Revolution Medicines’s price movement after its last earnings report?
Revolution Medicines reported an EPS of -$1.86 in its last earnings report, missing expectations of -$1.581. Following the earnings report the stock price went down -1.056%.
Which hedge fund is a major shareholder of Revolution Medicines?
Currently, no hedge funds are holding shares in RVMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Revolution Medicines Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$158.82 (6.86% Upside)
$158.82 (6.86% Upside)
Blogger Sentiment
Bullish
RVMD Sentiment 60%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 977.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $607.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 29.0%
Last 30 Days ▲ 21.8%
Last 30 Days ▲ 21.8%
News Sentiment
Very Bullish
Bullish news 97%
Bearish news 3%
Bearish news 3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
312.34%
12-Months-Change
Fundamentals
Return on Equity
-63.10%
Trailing 12-Months
Asset Growth
-7.49%
Trailing 12-Months
Company Description
Revolution Medicines
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
RVMD Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong clinical and operational momentum: multiple registrational trials, regulatory designations (Breakthrough Therapy and a commissioner priority voucher), promising early clinical data (notably zoldonrasib combination responses), new compounds entering the clinic, and a solid cash position supplemented by a large Royalty Pharma commitment. Offsetting these positives are substantially higher R&D and G&A spending, a materially wider net loss, and elevated 2026 operating expense guidance as the company scales clinical and commercial activities. Clinical uncertainties remain (OS-driven readout timing, potential crossover risk, and difficult CRC biology), but the balance of progress and funding to execute the plan led management to accelerate investments. Overall, progress and available capital appear to outweigh the near-term financial drag from higher expenses.View all RVMD earnings summariesRVMD Stock 12 Month Forecast
Average Price Target
$158.82
▲(6.86% Upside)
Technical Analysis
Ownership Overview
2.28% Insiders
20.94% Mutual Funds
0.14% Other Institutional Investors
63.21% Public Companies and Individual Investors